ArticleCureus2024
An Unusual Presentation of Juvenile Systemic Lupus Erythematosus.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic lupus erythematosus (SLE) is an autoimmune disease involving multiple organ systems that often mimic other conditions. The majority of patients with SLE show mucocutaneous manifestations, fatigue, fever, rheumatological manifestations, and weight loss as initial symptoms. SLE is classically managed medically with hydroxychloroquine, glucocorticoids, and/or immunosuppressives. Juvenile-onset systemic lupus erythematosus (jSLE) patients, who account for about 20% of SLE patients, tend to have earlier development of end-organ damage, and increased need for immunosuppressive therapies. We present a 12-year-old woman with a history of atopic conditions who initially presented for treatment of mild gastritis and a duodenal ulcer diagnosed by esophagogastroduodenoscopy (EGD). Several months later, the patient developed hematological abnormalities and rashes classically associated with SLE. Healthcare providers need to be aware of the distinct features of jSLE and modalities of treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.